Radioligand developability OS for radiopharma teams to rank binders, choose isotope pairs, and reach GMP-ready first-in-human studies.

1. Radiopharma teams are now combining AI discovery with radionuclide production, GMP manufacturing, and clinic translation at partnership formation, which creates demand for a system that coordinates those handoffs from day one.
2. The source explicitly says radiopharmaceuticals demand unusual precision, stability, and druggability, so generic discovery outputs are no longer enough for the first buyer workflow.
3. Planned pipelines spanning Gallium-68, Zirconium-89, Copper-64, and Rhenium-186 increase the number of viable design branches, making early program-selection software more valuable.
4. The partnership elevates GMP manufacturing and clinical translation as core assets, which means software that de-risks those downstream steps can attach to real budget and timeline pressure right now.

Catalyst. Sanyou Bio and Baiyunshan Xihe are explicitly stitching AI discovery, radionuclide production, GMP manufacturing, and clinical translation into one partnership, which turns the missing decision layer between those steps into an urgent budgetable workflow.

The startup would sell software plus expert workflow templates for teams moving a radioligand from binder shortlist to first-in-human package. Customers would upload target-molecule data, planned indications, intended isotope options, and vendor or site constraints; the product would return a developability score, the most viable diagnostic-therapy pairing, critical experiments, and a sequenced CMC workplan. It would also track which tasks belong with internal scientists, isotope suppliers, CDMOs, and nuclear medicine sites, so teams see early where a program will fail on shelf life, labeling yield, or site logistics instead of learning after contracts are signed. The initial product is not a wet-lab replacement or a full ELN; it is the program-level decision cockpit that keeps discovery, CMC, and clinical translation aligned around one asset. Over time, the company builds a proprietary dataset on which binder-isotope-chelator combinations actually advanced, stalled, or had to be reformulated.

What's different. Discovery-AI vendors generate binders, CROs and CDMOs execute work packages, and project managers chase timelines, but none of them owns the cross-functional decision of whether a radioligand program is truly developable before the lab burn begins. This startup wins by becoming the system of record for binder-to-isotope-to-site readiness, with explicit tradeoffs across chemistry, manufacturability, and first-clinic operations. Its moat grows from proprietary outcome data on which developability patterns predict delays, reformulations, or successful translation across many radiotheranostic programs.

Jobs to be done

flowchart LR
  Buyer[Head of CMC] --> Pain[Discovery, isotope, GMP, and site decisions are fragmented]
  Pain --> Product[Radioligand developability OS]
  Product --> Outcome[Faster pre-IND readiness and fewer program resets]

Executive takeaways

• China radiopharma is moving from scattered assets to integrated discovery-manufacturing-clinical stacks, but the neutral developability layer is still missing [1][2][4].
• The pain is real, yet the software-only beachhead is narrow; the venture case depends on becoming the shared coordination and data layer across CDMOs, isotope suppliers, and sites rather than a standalone scoring widget [8][9][18][21][35].
• China is a credible launch geography because nuclear medicine capacity is already large and radiopharma company formation accelerated after policy support, even though supply and talent remain bottlenecks [3][4][5][7].
• Budget likely exists inside adjacent spend on digital lab systems, CDMO work, isotope supply, and radiopharma consulting, so the startup can sell against avoided rework rather than inventing a net-new software category [12][17][18][21][22].
• Competition is intense in adjacent layers—horizontal R&D platforms, CDMOs, and consultants—but direct competition for a vendor-neutral binder-to-isotope-to-site decision cockpit is still limited [12][14][17][18][21][40].
• The biggest adoption risks are sparse standardized outcome data, localized regulatory/site variance, and buyer temptation to keep the work inside services vendors instead of a separate platform [5][7][33][34][35].

Market definition

China-first workflow software for pre-IND radioligand programs, sitting between generic R&D informatics and radiopharma service execution. It helps teams decide whether a binder/isotope/chelator path is likely to survive GMP, supply-chain, and first-site constraints before they commit scarce wet-lab and CDMO spend [1][7][8][9][40].

Customer and buyer

Primary users are heads of CMC/translational development and program managers at emerging radiopharma companies because China’s capacity is growing but talent, isotope supply, and translation know-how remain uneven [3][4][5][7]. The economic buyer is more likely the Head of Radiopharmaceuticals or CDO than IT, because the spend competes with CDMO, isotope, and pre-IND milestone budgets [18][21][22].

Buying triggers

• A lead binder is nominated and the team must choose among multiple isotope, chelator, and workflow branches before committing lab and vendor budgets. [1][36][37][39][54][68][73][77]
• The program shifts from discovery into pre-IND execution and separate CDMO, isotope-supply, GMP, and site-readiness owners need one integrated plan. [1][8][9][18][19][21][35][40]
• A manufacturing, quality, or isotope-supply shock makes the cost of fragmented planning immediately visible to management and investors. [10][25][26][27][28][29][31]

Willingness to pay

Willingness to pay is plausible because radiopharma entrants already spend against adjacent categories that map directly onto the proposed wedge: digital lab/CMC systems, CDMO process development, isotope-enabled manufacturing, and specialist strategy or regulatory support. A tool that kills a non-viable path earlier or prevents a manufacturing/site reset can draw from existing program budgets rather than speculative AI spend [12][17][18][21][22]. [12][17][18][21][22]

Category dynamics

Growth signal 13.2% CAGR for the radioligand therapy market (2025-2035) as a top-down category proxy

Validation signals

• Sanyou Bio and Baiyunshan Xihe are already packaging AI discovery, radionuclide production, GMP manufacturing, and clinical translation into one partnership structure.
• China’s radiopharma company base expanded from roughly 20 to nearly 100 in five years, indicating a growing local buyer universe even if many are still early.
• Novartis, BMS, and Lilly have all made large radiopharma infrastructure or acquisition bets, validating strategic urgency around the modality.
• A major referral center built a dedicated theranostics patient-management system because manual eligibility, records, safety, and scheduling workflows no longer scaled.

Regulatory & technical constraints

• Any system that touches regulated clinical-investigation workflows needs trustworthy electronic records, signatures, and human-accountable audit trails.
• Finished PET and related radiopharmaceutical products still require explicit controls and acceptance criteria, so the software cannot be cavalier about release-relevant data.
• Short half-lives and isotope-specific manufacturing footprints make central-versus-local production and delivery a core technical constraint, not an afterthought.
• Chelator chemistry, bioconjugation, radiolysis risk, and half-life matching materially affect whether a promising binder is truly translatable.

The market is fragmented between horizontal R&D clouds, scientific workflow platforms, radiopharma CDMOs, and specialist consultants. That means the white space is not “more lab software,” but a vendor-neutral decision cockpit sitting upstream of execution vendors and downstream of discovery data [12][14][17][18][19][21][22][35].

Why incumbents do not win by default

• Horizontal R&D clouds. Benchling- and Dotmatics-class platforms are strong at data orchestration and lab workflows, but they do not win by default on isotope-specific developability logic or nuclear-medicine site readiness.
• Digital lab and CMC informatics. Sapio-class deployments prove that regulated biopharma labs buy traceable digital workflows, yet those platforms still stop short of a radiopharma-specific binder-to-isotope decision layer.
• Radiopharma CDMOs. Nucleus-, NorthStar-, and Eckert-class providers can execute development and manufacturing, but they are not neutral across vendor choice and usually monetize downstream work rather than earlier no-go decisions.
• Specialist consultants and CROs. Bracken-class consultants and other specialists can fill strategic or operational gaps, but their model is people-heavy and does not naturally compound into a reusable cross-customer data asset.
• Large pharma internal stacks. Novartis, BMS, and Lilly are building internal manufacturing and radioligand capabilities, which validates strategic importance but also means smaller startups need a third-party control layer if they lack those internal assets.

Radioligand Developability OS sells a China-first decision and workflow layer for 20-80 person radiopharma teams taking their first peptide or antibody theranostic program from hit selection into pre-IND CMC planning. The researched pain is credible: discovery, isotope selection, chelator design, GMP, and site-readiness sit across separate vendors and teams, so programs often learn manufacturability or logistics failure too late. The first product should be explanation-first software that ingests binder data, isotope options, vendor constraints, and site requirements, then scores viable branches and generates a cross-vendor translation plan. The first beachhead is narrow by design: China teams planning Ga-68 or Zr-89 imaging with Cu-64 or Re-186 therapy follow-ons, because that is where the buying trigger, domain templates, and partner network can be validated fastest. Go-to-market must sell against avoided rework and pre-IND timeline compression, with founder-led sales to heads of CMC or translational development and referrals from CDMOs, isotope suppliers, and regulatory advisors. Research supports an estimated $4.6M China-first SAM and a $2.2M year-3 SOM, but not a broad venture case unless the company proves repeatable deployments and expansion beyond this first workflow. The central operating risk is that buyers may prefer CDMOs or consultants to own the workflow unless the product demonstrably shortens decision cycles and reduces reopened work packages. Evidence is still missing on exact budget owners and active account depth, so the company should be funded as a pre-seed validation build rather than a scale-ready platform bet.

Problem

• First-program radiopharma teams must choose binder, isotope, chelator, GMP path, and site workflow before they have integrated data or aligned vendors, so fatal developability issues surface only after wet-lab and CDMO spend.
• Current alternatives—spreadsheets, consultant memos, and vendor-specific project plans—optimize one function at a time and give management no neutral view of cross-branch tradeoffs or pre-IND readiness.

Solution

• Provide a vendor-neutral workspace that ingests binder, isotope, chelator, dosimetry, GMP, and site inputs, scores the most viable diagnostic-therapy branches, and highlights the experiments required before committing program capital.
• Generate a governed cross-vendor translation plan with task ownership, critical-path milestones, and audit trails so discovery, CMC, isotope suppliers, CDMOs, and first sites work from one program model.

Why we win

• Horizontal R&D clouds digitize lab data and CDMOs execute work, but neither owns the decision of whether a radioligand path is translatable before execution contracts are signed.
• Starting with one molecule class, one geography, and a narrow isotope set lets the company build trustworthy rules and partner templates faster than a broad ELN, LIMS, or global-services platform.
• Each live program compounds a proprietary dataset of binder-chelator-isotope outcomes, vendor constraints, and site blockers that can improve win rate and reduce deployment time.

Milestones

flowchart LR
  Wedge[China first-program wedge] --> MVP[Explanation-first developability MVP]
  MVP --> Proof[Faster pre-IND plans and fewer resets]
  Proof --> Expansion[Global radiopharma control layer]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 5 of the first 15 qualified China beachhead accounts must confirm that first-program translation planning already has a named budget owner and cannot stay inside ad hoc spreadsheets.
• The first 2 paid pilots must reduce time from lead-binder nomination to approved pre-IND workplan by at least 30%.
• At least 70% of required decision inputs for the beachhead must be ingestible from existing spreadsheets, assay outputs, and vendor reports without an ELN or LIMS replacement.
• At least 2 CDMOs or isotope suppliers must agree to participate as referral or template partners without forcing the company into white-label services.
• Paid pilot-to-annual-production conversion must reach at least 50% with year-one program revenue at or above the low end of the researched $120k-$180k range.

Open diligence questions

• How many China radiopharma companies actually fit the first-program, vendor-dependent ICP and control their own pre-IND budget?
• Which KPI unlocks budget fastest in practice: avoided rework, faster no-go decisions, or fewer manufacturing and site surprises?
• What minimum data inputs are reliably available before CDMO scoping, and who controls them?
• Will CDMOs and isotope suppliers refer opportunities or bundle competing planning logic into their own services?
• How quickly must the product support alpha emitters or ex-China workflows to avoid market exhaustion?

Model sanity

• Revenue engine. Base-case revenue comes from growing from 3 to 12 active paid programs at roughly $180K blended ARPU, not from assuming broad ex-China platform revenue too early.
• Must go right. The first 6-8 active programs must share enough isotope, CDMO, and site-template structure that gross margin can rise from 60-65% in Y1 pilots to about 70% by late Y2.
• Model breaks if. If the sales cycle stretches toward 9 months or ARPU falls toward $165K, downside cash falls to roughly break-even on the current $2.2M pre-seed.
• Next-round proof. The next financing story is 8 active programs by Q4Y2, sub-30-day deployments, and at least one partner-sourced production path that validates the channel thesis.

Scenarios

Sensitivity

flowchart LR
  Accounts[ICP accounts] --> Pilots[Paid pilots]
  Pilots --> Programs[Active paid programs]
  Programs --> Revenue[Subscription and review-fee revenue]
  Revenue --> GrossProfit[Gross profit after scientific review and onboarding]
  GrossProfit --> Cash[Cash for product and GTM]

Flags: The model exits Y3 at $1.89M of recognized revenue, still below the researched $2.2M SOM, because it does not assume broad ex-China expansion before proof. · The business is still EBITDA-negative in Y3, so the next round depends on milestone proof and partner-led repeatability rather than near-term profitability. · One lost production program would move revenue and cash materially because the beachhead remains concentrated at only 12 active programs by Y3. · Gross margin only reaches the target range if scientific review and implementation work become template-driven by the third or fourth deployment.

• Sparse outcome data. Early radiopharma programs generate limited standardized data, which could make developability scores feel too heuristic at first. Mitigation: Start as explanation-first workflow software with expert rules and structured templates, then learn from each customer's actual binder-isotope and CMC outcomes.
• Services-heavy buying behavior. Many teams may prefer to hand translation planning to CDMOs or consultants instead of buying software. Mitigation: Position the product as the neutral control layer above suppliers and sell against avoided rework, timeline slips, and partner coordination failures.
• Regulatory and isotope variability. Isotope availability, labeling protocols, and site requirements vary by program and region, which can limit a one-size-fits-all product. Mitigation: Launch in one geography and a narrow isotope set, then expand the rules and partner network market by market.